University Hospital Reina Sofia
Welcome,         Profile    Billing    Logout  
 12 Trials 
34 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rodriguez, Juan M
BRISOTE, NCT06750289: Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

Not yet recruiting
3
400
US
ICS-LABA, benralizumab, Placebo for Benralizumab
AstraZeneca
Eosinophilic Asthma
10/27
10/27
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Active, not recruiting
3
407
Europe, US, RoW
IO102-IO103, Pembrolizumab
IO Biotech, Syneos Health, Merck Sharp & Dohme LLC
Metastatic Melanoma, Unresectable Melanoma
07/25
09/27
NCT04247542: ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

Completed
2
53
US
Ibezapolstat, ACX-362E, Vancomycin, Vancomycin oral
Acurx Pharmaceuticals Inc.
Clostridium Difficile Infection
10/23
11/23
PATRICIA, NCT02448420 / 2014-005006-38: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

Completed
2
73
Europe
Palbociclib, Ibrance, Trastuzumab, Herceptin, Endocrine therapy, ET, Chemotherapy, CT, Antibody-Drug Conjugates, Trastuzumab emtansine (TDM-1)
SOLTI Breast Cancer Research Group
Metastatic Breast Cancer
09/23
11/23
NCT04781387: Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

Active, not recruiting
2
108
Canada, US
CRS3123, Active Comparator
Crestone, Inc, National Institute of Allergy and Infectious Diseases (NIAID)
Clostridioides Difficile Infection
02/24
04/24
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
NCT05896657: Modulation of Reproductive Microbiota by Ligilactobacillus Salivarius CECT5713

Active, not recruiting
N/A
70
Europe
Ligilactobacillus salivarius CECT5713, Placebo
Universidad Complutense de Madrid, Hospital San Carlos, Madrid, Biosearch S.A.
Abortion, Spontaneous, Abortion in First Trimester, Infertility Unexplained
05/23
12/23
TRANSFORM, NCT06112418: A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

Recruiting
N/A
7500
US
The Cleerly CAD Staging System
Cleerly, Inc., CPC Clinical Research
Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
03/29
03/29
Sánchez, Fernando
HIDRA360, NCT05832164: Effectiveness of a Multifactorial Intervention in Frailty Individuals With HIV Infection:

Recruiting
N/A
61
Europe
Multifactorial intervention
Hospital Costa del Sol
Frailty Syndrome, HIV Infections
10/23
01/24
Nieto, Maria Jesus Rodriguez
GECOP-MMC, NCT05250648 / 2019-004679-37: Clinical Trial on HIPEC with Mitomycin C in Colon Cancer Peritoneal Metastases

Recruiting
4
216
Europe
complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes, complete cytoreductive surgery without HIPEC
Hospital Universitario de Fuenlabrada, Instituto de Investigación Hospital Universitario La Paz
Peritoneal Carcinomatosis, Colon Cancer
10/29
10/29
NCT04098146: Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection

Recruiting
N/A
300
Europe, US
Surgical Resection and Reconstruction
AO Innovation Translation Center
Mandibular Reconstruction, Segmental Mandibular Defects
06/30
12/30
Rodriguez, Elena
NCT05649020: ED50 of Intratecal Prilocaine in Ultrasound Fusion Prostate Biopsy

Recruiting
4
90
Europe
Dose of prilocaine, ED50 of intrathecal hyperbaric prilocaine in ultrasound fusion guided prostate biopsy
Hospital General Universitario Gregorio Marañon
Evaluate Requirements of 2% Prilocaine in MR-UF Prostate Biopsy
12/23
03/24
Cazzaniga, Marina
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
YAPPETIZER, NCT03358017: Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

Completed
2
54
Europe
Zoledronate, zoledronic acid, Atorvastatin 80mg, Standard neoadjuvant cht
Mario Negri Institute for Pharmacological Research, Associazione Italiana per la Ricerca sul Cancro
Triple Negative Breast Cancer
06/21
07/23
ABIGAIL, NCT04603183 / 2020-001648-24: ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

Active, not recruiting
2
162
Europe
Abemaciclib, Verzenios, Paclitaxel, Paclitaxel Teva, Letrozole, Fulvestrant
MedSIR, Eli Lilly and Company
Breast Cancer Metastatic
06/24
06/25
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc., Seagen, Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
PHERGAIN-2, NCT04733118 / 2020-003205-66: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Active, not recruiting
2
393
Europe
Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla
MedSIR, Hoffmann-La Roche
Early Breast Cancer
09/25
03/28
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
ELVN-002-003, NCT06328738: ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Recruiting
1
275
Europe, US, RoW
ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin
Enliven Therapeutics
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
01/27
07/28
ELVN-002-001, NCT05650879: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Recruiting
1
198
Europe, US, RoW
ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1
Enliven Therapeutics
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
07/26
07/26
HERMIONE-13, NCT05173103: Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Recruiting
N/A
150
Europe
University of Milano Bicocca
Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
01/24
01/24
HERMIONE-10, NCT05302778: Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer

Recruiting
N/A
200
Europe
University of Milano Bicocca, EISAI s.r.l.
Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer
12/23
12/23
Gracia, José Luis Pérez
PHITT, NCT03017326 / 2016-002828-85: Paediatric Hepatic International Tumour Trial

Active, not recruiting
3
450
Europe, RoW
Cisplatin, Doxorubicin, Carboplatin, 5Fluorouracil, Vincristine, Etoposide, Irinotecan, Gemcitabine, Oxaliplatin, Sorafenib
University of Birmingham, Fundació Institut Germans Trias i Pujol, University Hospital Munich, University Hospital, Bonn, University of Kiel, University Hospital Tuebingen, University of Padova, Ludwig-Maximilians - University of Munich, Medical University of Gdansk, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Motol University Hospital, Prague, Rennes University Hospital, Children's University Hospital, Ireland, University of Oslo, Princess Maxima Center for Pediatric Oncology, Andaluz Health Service, Swiss Pediatric Oncology Group, Gothia Forum - Center for Clinical Trial, The Leeds Teaching Hospitals NHS Trust, Bambino Gesù Hospital and Research Institute, Newcastle University Centre for Cancer, Newcastle, Experimental Cancer Medicine Centres, XenTech, Evry
Hepatoblastoma, Carcinoma, Hepatocellular
08/26
08/27
Mateos, Maria V
PHITT, NCT03017326 / 2016-002828-85: Paediatric Hepatic International Tumour Trial

Active, not recruiting
3
450
Europe, RoW
Cisplatin, Doxorubicin, Carboplatin, 5Fluorouracil, Vincristine, Etoposide, Irinotecan, Gemcitabine, Oxaliplatin, Sorafenib
University of Birmingham, Fundació Institut Germans Trias i Pujol, University Hospital Munich, University Hospital, Bonn, University of Kiel, University Hospital Tuebingen, University of Padova, Ludwig-Maximilians - University of Munich, Medical University of Gdansk, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Motol University Hospital, Prague, Rennes University Hospital, Children's University Hospital, Ireland, University of Oslo, Princess Maxima Center for Pediatric Oncology, Andaluz Health Service, Swiss Pediatric Oncology Group, Gothia Forum - Center for Clinical Trial, The Leeds Teaching Hospitals NHS Trust, Bambino Gesù Hospital and Research Institute, Newcastle University Centre for Cancer, Newcastle, Experimental Cancer Medicine Centres, XenTech, Evry
Hepatoblastoma, Carcinoma, Hepatocellular
08/26
08/27
NCT06413706: A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Recruiting
2
45
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Temozolomide
Eli Lilly and Company
Glioma
07/27
02/28
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Oct 2024 - Dec 2024 : Data for SLE
Hourglass Jul 2024 - Sep 2024 : Data for CLE
Completed
2
456
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
11/24
WILLOW LTE, NCT05540327 / 2022-000239-21: The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE

Recruiting
2
532
Europe, Japan, US, RoW
M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA
Systemic Lupus Erythematosus
04/25
04/25
CARTBCMA-HCB-01, NCT04309981: Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.

Active, not recruiting
1/2
73
Europe
Adult differentiated autologous T-cells with anti-BCMA specificity, CARTBCMA
Sara V. Latorre, Fondos ARI (Assistencia Recerca Intensiva), Instituto de Salud Carlos III, Fondo Social La Caixa
Relapsed/Refractory Multiple Myeloma
04/25
04/25
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Completed
1
106
Europe, US
Tinostamustine, EDO-S101
Mundipharma Research Limited
Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma
05/23
11/23
NCT04887259 / 2020-004583-26: Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Checkmark Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark First patient dosing for P1/2a for relapsed refractory CLL
More
Terminated
1
16
Europe, US
LAVA-051, Interleukin 2
Lava Therapeutics, LAVA Therapeutics N.V., LAVA Therapeutics B.V.
Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
09/23
09/23

Download Options